Click here if you are having trouble viewing this message.

June newsletter

This month we were excited to announce that Dr Jonathan Appleby will be joining CGT Catapult in October 2018 as Chief Scientific Officer. Dr Appleby will bring decades of industry experience to the role which he talks more about in this interview, along with the challenges he expects to face and what he is hoping to achieve.

It was great to take part in the first Medicines and Manufacturing Industry Partnership (MMIP) conference on 7 June. As part of the event delegates were given a tour of the CGT Catapult manufacturing centre a key facility in delivering skills and training needs recommended by the group.

We also took part in the International Business Festival alongside colleagues from Department for Business Energy and Industrial Strategy, Department for International Trade and Innovate UK where we provided tours of the CGT Catapult manufacturing centre in virtual reality. Watch this video to take your own virtual tour.

We are looking forward to attending the Tissue and Cell Engineering Society Conference in Keele next week, and you can also catch members of the team at On Helix. Along with Stevenage Bioscience Catalyst, we will be discussing the manufacturing cluster and how through collaboration, the cluster is supporting the development and manufacture of advanced therapies. Please visit the website for the full agenda.

Share this email on social media

News

New CSO for CGT Catapult, meet Dr Jonathan Appleby
Dr Jonathan Appleby will join CGT Catapult as CSO in October 2018. Dr Jonathan Appleby is currently the Chief Scientific Officer for Cell and Gene Therapy at the GSK Rare Diseases Unit.
Read the press release

Why is China a focus for CGT Catapult?
CCO Dr Jacqueline Barry tells the story of CGT Catapult in China, discussing why the country is increasingly a global focus point for new medicines development. She also shares some of her personal experiences.
The story of CGT Catapult in China

Webinar: Funding, commercialisation and market access
Dr Panos Kefalas discussed the challenges that need addressing in early development to overcome the high manufacturing costs of advanced therapies in the third webinar in this three part series.
Listen to the webinar

EMAs PRIME scheme: a two year overview
The main regulatory story over the last month has been the EMA's review of the priority access to medicines scheme. This and more stories from the EMA and regulatory authorities around the world in our regulatory round up.
Regulatory news

Upcoming events

Tissue and Cell Engineering Society Conference 2018
2 - 3 June 2018
Dr Lee Dunham, Business Development and Transactions Executive (UK North) and Dr Richard Harrison, Business Development and Transactions Executive (UK South) will both be attending this event. Contact us to arrange a meeting.

On Helix
10 -11 June 2018
Early clinical development: Cell and gene therapies
Join Dr Michael Bennet, Director of Business Development, Cell and Gene Therapy Catapult and Sally Ann Forsyth, CEO, Stevenage Bioscience Catalyst as they discuss the unique challenges faced by ATMP developers in early clinical development. Find out more.

+44 (0) 203 728 9500
12th Floor Tower Wing, Guy’s Hospital, Great Maze Pond, London SE1 9RT

The Cell and Gene Therapy Catapult takes your data very seriously, you can read how we may use it in our privacy policy. If you no longer want to hear from us unsubscribe here.